Analgesics Market Synopsis
\nAnalgesics Market Size Was Valued at USD 87.59 Billion in 2023, and is Projected to Reach USD 131.29 Billion by 2032, Growing at a CAGR of 4.6% From 2024-2032.
\nThe analgesics market means the world market involving the manufacture, distribution, and sales of medicines, which help to relieve pain without the administration of anaesthetics. These drugs are OTC and prescription medication and are easily accessed to manage several issues such as migraines, muscle and joint pains, arthritis, and neuralgia among others, and postoperative pain. They are classified into non-opioid analgesics; which include acetaminophen, and NSAIDS, and opioid analgesics which are used for severe pain.<\/p>\n
Market analysis revealed that the analgesics market has been steady in its growth all over the world because of the growing need for pain relief products in different therapeutic segments. Such factors as increase in the prevalence of chronic diseases, an ageing population that is susceptible to diseases such as arthritis and increase in surgical procedures globally. It has also increased the desire to take OTC analgesics including non-opioid analgesics such as Ibuprofen and aspirin due to rising worries of health complications that result from opioids such as narcotics.<\/p>\n
Technological progressions in the form of new extended-release formula and novel combination drugs and topical pain management formulations have shaped the market progression from a higher level. However, new knowledge on pain management and a changing trend towards self-medication in growing economies also plays a positive role towards this. Governments and healthcare companies are also furthering efforts of accessible pain therapies consequently, enhancing overall development of the analgesics market. Nonetheless, the recent opioid problem mainly in some specific countries especially in the United States has seemed to introduce more regulates which may limit the general market of prescription opioids.<\/p>\n
Analgesics Market Trend Analysis
\nShift Towards Non-Opioid Alternatives<\/p>\n
One of the tendencies that can be outlined in the analgesics market is the growing interest to non-opioid drugs. Specifically, while patients fear the development of addiction to opioids and statistically confirmed increased incidence of primary and secondary health risks, doctors and patients in pain are in search of less hazardous pain-modifying modalities. Other classes on analgesics are opiates, non-opioid analgesics which include NSAIDS, acetaminophen and emerging classes of drugs like cannabinoid-based drugs. This trend is due to increased consciousness of the side effect of opioids and the governments\u2019 policies to reduce the use of opioids. Companies are also continuing to spend money on research and development to develop better non opioid pain management drugs which are an option to opioid drugs.
\nGrowth in Emerging Markets<\/p>\n
One of the biggest threats is serviced by increasing the focus on the constructive development of healthcare infrastructure and the availability of pain management therapies in emerging markets including Asia-Pacific and the Latin American regions. These regions continue to grow economically, experience enhanced health care services and have an increasing population base with growing disposable income, which is expected to drive up the demand for over the counter as well as prescription-based pain killers. Governments are also investing efforts to improve requirements of the efficacious and safe availability of necessary drugs, and ancillary pain management therapies as portions of strategies for population health. Furthermore, the lower adoption of innovations in pain control in these locations is a clear market opportunity for multinational pharmaceutical organizations to capture new market share to provide efficient and appropriate pain management solutions to the increasing population of sufferer patients.
\nAnalgesics Market Segment Analysis:
\nAnalgesics Market Segmented on the basis of type, drug class and indication.
\nBy Type, Prescription segment is expected to dominate the market during the forecast period<\/p>\n
By type, prescription analgesics shall continue to lead the market over the forecast period based on the increasing prevalence of chronic and severe pain that cannot be addressed by over-the-counter drugs. Non-methademic analgesics, opioids and other preparations, are customarily required to address postoperative pain, cancer pain, as well as rheumatoid arthritis and other chronic pains for which a paracetamol tablet may not suffice. In addition, growth in prescription pain management therapies, such as extended-release formulations and tailored therapy, accelerates the growth of this segment. Also, as healthcare providers give attention to better and improved pain management while respecting strict laws and particularly, concerning regulation of opioids the prescribed analgesics market will continue to have steady growth across both the developed and developing countries.
\nBy drug class, the Opioids segment expected to held the largest share <\/p>\n
By drug class, opioids segment is expected to dominate the analgesics industry because these drugs act effectively for moderate to severe pain management, especially during postoperative care, cancer treatment, and chronic pain sufferers. Opioids are used where other methods of pain relief fail which makes opioids a vital tool for managing pain in health care facilities. However, there is rising apprehensions for addiction and strictly regulated prescription controls over opioids The demand for these medicines however is not leaving because they offer unmatched relief from severe pain. Other factors such as new developments of abuse proof formulations, opioid prescription tracking and controlling policies play important roles in sustaining the market demand for opioid analgesics particularly in NA and Europe.
\nAnalgesics Market Regional Insights:
\nNorth America is Expected to Dominate the Market Over the Forecast period <\/p>\n
North America holds around 40% of the global analgesics market due to the increased consumption of painkiller pharmaceuticals; well-developed pharmaceutical companies; and increasing investments in healthcare research. Factors that have made them dominate the market include a strong base in the region’s already established healthcare systems and an emphasis on the effective management of pain. Meanwhile, the area\u2019s that demonstrate the fastest CAGR for the duration of the projection include Asia Pacific due to the growing demand for analgesics, increasing admission levels about the use of the products, elevating healthcare costs, and growing acceptation of pain remedies in new markets.
\nActive Key Players in the Analgesics Market <\/p>\n
Johnson & Johnson (USA)<\/p>\n
Pfizer Inc. (USA)<\/p>\n
GlaxoSmithKline (UK)<\/p>\n
Sanofi (France)<\/p>\n
Novartis AG (Switzerland)<\/p>\n
Bayer AG (Germany)<\/p>\n
AstraZeneca (UK)<\/p>\n
Boehringer Ingelheim (Germany)<\/p>\n
Merck & Co., Inc. (USA)<\/p>\n
Eli Lilly and Company (USA)<\/p>\n
Teva Pharmaceutical Industries Ltd. (Israel)<\/p>\n
Reckitt Benckiser (UK)<\/p>\n
Endo International plc (Ireland)<\/p>\n
Takeda Pharmaceutical Company (Japan)<\/p>\n
Sun Pharmaceutical Industries Ltd. (India)<\/p>\n
Other key Players
\nKey Industry Developments in the Analgesics Market:<\/p>\n
In Jun 2021, By creating its Consumer Health segment, Bayer increased its market share in India. Eli Lilli and the company entered negotiated a licensing arrangement with Asahi Kasei Pharma, a pharmaceutical business located in Japan, in January of 2021.<\/p>\n
In Jan 2021, Premier, an American healthcare improvement company, partnered with Pfizer. Following this collaboration, the companies would provide healthcare professionals with five necessary medications to help them meet both short-term and long-term demands for medications necessary for a variety of patient care interventions.<\/p>\n","protected":false},"excerpt":{"rendered":"
The analgesics market means the world market involving the manufacture, distribution, and sales of medicines, which help to relieve pain without the administration of anaesthetics.<\/p>\n","protected":false},"featured_media":22501,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-25310","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n